Literature DB >> 7530469

Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure.

P A Goldberg1, R J Nicholls, N H Porter, S Love, J E Grimsey.   

Abstract

A prospective randomised multicentre trial compared pre-operative radiotherapy followed by surgery with surgery alone for rectal cancer < or = 12 cm from the anal verge. Of 468 patients (mean age 67 years, range 31-94, 273 males) who met the entry criteria, 228 were randomised to radiotherapy (3 x 5 Gy over 5 days within 2 days of operation) followed by surgery, and 239 to surgery alone. Randomisation was unknown in 1 patient. Follow-up to death or 5 years was achieved in 454 (97%) patients. 31 (7%) of the 468 patients died within 30 days of operation (radiotherapy and surgery 21 [9%], surgery alone 10 [4%]; P < 0.05). Cardiovascular and thromboembolic complications were more common after radiotherapy and surgery (30, 13%) than after surgery alone (8, 3%; P < 0.005). Of the 280 patients who had curative surgery, 52% of those who had radiotherapy and surgery and 56% of those who had surgery alone survived 5 years (P = 0.88). 395 patients attended outpatients clinics at least once. Local treatment failure was identified during follow-up in 82 patients [31/185 (17%) radiotherapy and surgery; 51/210 (24%) surgery alone; P < 0.05]. It occurred in 33 of the 258 patients who had a curative resection and attended outpatients [radiotherapy and surgery, 11/120 (9%), surgery alone, 22/138 (16%); P = 0.08]. Long-term survival was unaffected, but long-term local recurrence was reduced by the addition of low-dose radiotherapy to surgery. Peri-operative mortality was, however, increased.

Entities:  

Mesh:

Year:  1994        PMID: 7530469     DOI: 10.1016/0959-8049(94)00312-s

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  32 in total

Review 1.  Optimising treatment for resectable rectal cancer: is preoperative therapy beneficial?

Authors:  S Y Ngan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  Management of colorectal cancer.

Authors:  A Melville; T A Sheldon; R Gray; A Sowden
Journal:  Qual Health Care       Date:  1998-06

3.  [Locally recurrent rectal carcinoma].

Authors:  Th Lehnert; M Golling; J Buchholz
Journal:  Chirurg       Date:  2004-01       Impact factor: 0.955

4.  Randomized study on preoperative radiotherapy in rectal carcinoma. Stockholm Colorectal Cancer Study Group.

Authors: 
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

5.  Local recurrence and survival after laparoscopic mesorectal resection forrectal adenocarcinoma.

Authors:  E C Poulin; C M Schlachta; R Grégoire; P Seshadri; M O Cadeddu; J Mamazza
Journal:  Surg Endosc       Date:  2002-02-28       Impact factor: 4.584

6.  Feasibility of adequate resectable rectal cancer treatment in a third-level hospital.

Authors:  J Gallego-Plazas; F Menárguez-Pina; A Maestre-Peiró; V González-Orozco; F Andreu; M J Escudero-Barea; M A Morcillo
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

7.  Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers.

Authors:  Conor P Delaney; Ian C Lavery; Antonio Brenner; Jeffrey Hammel; Anthony J Senagore; Robert B Noone; Victor W Fazio
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

8.  Adjuvant therapy for rectal cancer.

Authors:  Smitha S Krishnamurthi; Yuji Seo; Timothy J Kinsella
Journal:  Clin Colon Rectal Surg       Date:  2007-08

9.  Redefining contraindications to laparoscopic colorectal resection for high-risk patients.

Authors:  John H Marks; Ulana B Kawun; Wajdi Hamdan; Gerald Marks
Journal:  Surg Endosc       Date:  2008-03-18       Impact factor: 4.584

10.  [Problems in the treatment of upper rectal carcinoma].

Authors:  T Junginger; P Hermanek
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.